Results 151 to 160 of about 19,263 (243)

Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies. [PDF]

Front Oncol
Sánchez-Tabernero M, Zamanillo I, Sánchez-Pina JM, Alonso-Fernandez R, López-Muñoz N, Corona M, Fernández-Guijarro M, Cedena MT, Cortijo S, Calbacho M, Martinez-Lopez J.   +10 more
europepmc   +1 more source

Natural Killer Cells in Cancer Immunotherapy [PDF]

, 2019
Arndt MA, Chester C, Cortez VS, D'Andrea A, Elsasser D, Ferrini S, Gao Y, Hartmann F, Lotze MT, Miller JS, Orr MT, Seillet C, Soiffer RJ, Soto EO, Weiner LM, Yron I   +15 more
core   +1 more source

Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma [PDF]

Junnan Li, Xin Wang, Shuangnian Xu, Dongfeng Zeng, Yi‐Hsin Yang   +4 more
openalex   +1 more source

Will Daratumumab be the next game changer in early thymic precursor‐acute lymphoblastic leukaemia? [PDF]

, 2019
Sumeet Mirgh, Rayaz Ahmed, Narendra Agrawal, Vishvdeep Khushoo, Ambar Garg, Shinto Francis, Narender Tejwani, Neha Singh, Dinesh Bhurani   +8 more
openalex   +1 more source

Daratumumab in the Treatment of Multiple Myeloma: Real World Evidence (2018-2024) at the a. Gemelli Polyclinic (Rome) and Comparison With Registration Studies. [PDF]

Hosp Pharm
Favia M, Sperandeo M, Cerbo LD, Sabia A, Musicco F, Za T, Campopiano R, Rossi E, Pani M, Tarantino D.   +9 more
europepmc   +1 more source

The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma [PDF]

, 2021
Boccadoro, M., Bonello, F., Bringhen, S., Castellino, A., Celeghini, I., D'Agostino, M., Grasso, M.   +6 more
core   +1 more source

Case Report: Dual impact of daratumumab in early T-cell precursor acute lymphoblastic leukemia -- consolidation therapy achieves remission and eliminates donor-specific HLA antibodies. [PDF]

Front Immunol
Wong KL, Tuy T, Quek J, Linn YC.
europepmc   +1 more source

Evaluation of the reporting quality of randomized controlled trials for treatments in multiple myeloma published the last 5 years using the CONSORT 2010 statment [PDF]

, 2016
Ντέλλας, Παναγιώτης
core   +1 more source

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

, 2016
Christopher R. McCudden, Amy Axel, Dominique Slaets, Thomas Dejoie, Pamela L. Clemens, Sandy Frans, Jaime Bald, Torben Plesner, Joannes F.M. Jacobs, Niels W.C.J. van de Donk, Philippe Moreau, Jordan M. Schecter, Tahamtan Ahmadi, A. Kate Sasser   +13 more
openalex   +2 more sources

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

, 2019
Hareth Nahi, Michael Chrobok, Charlotte Gran, Johan Lund, Astrid Gruber, Gösta Gahrton, Per Ljungman, Arnika Kathleen Wagner, Evren Alici   +8 more
openalex   +2 more sources